Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
| Image |  |
|---|---|
| Description | scientific article published on 12 November 2018 |
| Author/s |
author: Mathias Hänel Jan Moritz Middeke Katja Sockel Uta Oelschlägel Richard Noppeney Marika Mende Lars Fransecky Johannes Schetelig Katharina S Götze Christian Thiede Anne Sophie Kubasch Matthias Stelljes Ulrich Dührsen Christoph Röllig Uwe Platzbecker Martin Bornhäuser Malte von Bonin Tilmann Bochtler Claudia D Baldus Gerhard Ehninger Gesine Bug Alwin Krämer Christoph W Groth Hubert Serve |
| Publication date | November 12, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |